This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Background: Our High Throughput proprietary I-STARTM (in-situ therapeutic antibody rescue) technology platform enables the
discovery of fully human therapeutic antibody candidates eliminating the need for lengthy processes of humanization, affinity
maturation and other optimization. The interrogation of the memory B cell compartment allows scanning the repertoire for antibodies
in a donor and the identification of antibodies often directed against novel, rare, including conformational epitopes. Using I-STARTM
we have successfully identified the first truly broad spectrum anti-influenza virus mAb, TCN-032, and a large number of highly potent,
broadly neutralizing antibodies (bNAbs) against HIV. We will present our clinical influenza program illustrating the advantages of
TCN-032 is a first in class drug targeting the M2 protein with a new mechanism of action. This high affinity, high avidity fully
human IgG1κ mAb demonstrates nanomolar ADCC and CDC in vitro activity. In vivo, prophylactic and therapeutic efficacy was
confirmed in mice with seasonal including highly pathogenic H5N1 strains. The antibody recognizes 98% of all human, avian and
swine influenza A strains sequenced to date and has a high barrier to viral escape.
Fully human mAbs present a solid approach to defend against biothreat pathogens providing a high safety margin and reasonably
faster development times compared to small molecules. Theraclone?s I-STARTM technology can also contribute to vaccine engineering
and the development of diagnostics.
Bonavia is currently the head of the Biology group at Theraclone Sciences, developing therapeutic antibodies for infectious diseases. Previously,
Dr. Bonavia led antiviral programsfor respiratory syncytial virus, influenza virus, and Ebola virus at Novartis and Functional Genetics. He obtained his
Ph.D. in microbiology at the University of Colorado Health Sciences Center and after a postdoctoral trainingin retroviruses at Johns Hopkins Medical
Schoolhejoined the laboratory of viral diseases at NIH-NIAID to carry out research on HCoV-SARS. Dr. Bonavia has focused on R&D of small molecules
and biologics against respiratory and biodefense viruses with an emphasis on host-targets.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals